TrialOral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Trial details
- Registry ID
- NCT02244606
- Phase
- Phase 2
SCYX
Scynexis, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
7Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Trial details
- Registry ID
- NCT03059992
- Phase
- Phase 3
Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)
Trial details
- Registry ID
- NCT03363841
- Phase
- Phase 3
Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis
Trial details
- Registry ID
- NCT03672292
- Phase
- Phase 2
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
Trial details
- Registry ID
- NCT04029116
- Phase
- Phase 3
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
Trial details
- Registry ID
- NCT05178862
- Phase
- Phase 3
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Trial details
- Registry ID
- NCT05399641
- Phase
- Phase 3
Latest recorded trial changes
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
NCT05178862 · Scynexis, Inc.
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before
Measure: All-cause mortality (US FDA Only)
Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only)
+ After
Measure: All-cause Mortality Measure: Global Response at End of Treatment (EU European Medicines Agency [EMA] Only)
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
NCT05178862 · Scynexis, Inc.
Completion date type changed
− Before
Estimated
+ After
Actual
Primary completion date changed
− Before
31 Dec 2026
+ After
7 Nov 2025
Recruitment status changed
− Before
Active not recruiting
+ After
Terminated
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
NCT05178862 · Scynexis, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Enrollment · participant count changed
− Before
220 participants (planned)
+ After
68 participants (actual)
Recruitment status changed
− Before
Recruiting
+ After
Active not recruiting